Back to Results

Tengion Inc (TNGNQ)

Tengion Inc. was a biotechnology company focused on regenerative medicine and the development of neo-organs and related products designed to repair, regenerate, or replace damaged tissue and organs. Its pipeline included Neo-Kidney Augment, intended to help delay dialysis in patients with advanced chronic kidney disease, and Neo-Urinary Conduit, which was being studied in a Phase I clinical trial for use after bladder removal surgery. The company also had a licensing agreement with Children’s Medical Center Corporation covering certain tissue engineering patent and intellectual property rights. Founded in 2003 and headquartered in Winston-Salem, North Carolina, Tengion later filed for Chapter 7 liquidation in December 2014.


Stock Summary Fair Value Profitability & Growth Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Dividend Yield Market Cap
OTC-TNGN.Q
Not available
Not available
Not available
0.0%
0.402 K
Valuation • Fair Value

Tengion Inc (OTC-TNGN.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for Tengion Inc (OTC-TNGN.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Tengion Inc (OTC-TNGN.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Tengion Inc (OTC-TNGN.Q)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Tengion Inc (OTC-TNGN.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Events • Dividends

Dividend Profile for Tengion Inc (OTC-TNGN.Q)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Tengion Inc (OTC-TNGN.Q). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Tengion Inc (OTC-TNGN.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Tengion Inc (OTC-TNGN.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Tengion Inc (OTC-TNGN.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Tengion Inc (OTC-TNGN.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Tengion Inc (OTC-TNGN.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Tengion Inc (OTC-TNGN.Q) Stock FAQ

Data-supported answers about Tengion Inc (OTC-TNGN.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs

A reliable fair value estimate is not currently available for Tengion Inc (OTC-TNGN.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The latest available data indicates no current dividend yield for Tengion Inc (OTC-TNGN.Q).

The current market capitalization listed for Tengion Inc is 0.402 K.

The ticker symbol for Tengion Inc is OTC-TNGN.Q, and the stock is listed on OTC Markets.

Tengion Inc (OTC-TNGN.Q) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B